AKBA, SYBX, FGEN and FIXX among after-hours movers
- BySeeking Alpha-
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Technology, Basic Materials and Consumer Goods sectors led shares lower. At the close in NYSE,...
On the 30th of September, the Baupost Group sold all their 18 million Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares for $44 million at an average price of $2.51 per share. Shares...
Investors in Akebia Therapeutics (NASDAQ:AKBA), Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 15, 2021...
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).